human
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Objectives To evaluate the effect of association of tamsulosin/tadalafil taken daily compared with tamsulosin/placebo in the lower urinary tract with urodynamic study ( UDS ) . Methods All patients underwent baseline UDS before r and omization to tamsulosin 0.4 mg/tadalafil 5 mg ( Group 1 ; n = 20 ) or tamsulosin 0.4 mg/placebo ( Group 2 ; n = 20 ) once daily for 30 days . End-of- study UDS were performed on completion of the treatment period . The primary end point was to demonstrate changes in urodynamic variables in the voiding phase , detrusor pressure at maximum flow ( PdetQmax ) , and maximum flow rate ( Qmax ) , from baseline to week four . Results The primary outcome measure of this clinical trial , PdetQmax , showed a significant reduction in tamsulosin/tadalafil group ( 13 ± 17.0 ) compared to tamsulosin/placebo ( −1.2 ± 14.35 ) group ( P = 0.03 ) . Qmax increased in both groups , tamsulosin/tadalafil ( 1.0 ± 2.4 ) and tamsulosin/placebo ( 1.4 ± 2.4 ) , but the difference was not significant between treatment groups ( P = 0.65 ) . Total IPSS , storage , and voiding sub-score improved significantly in tamsulosin/tadalafil compared with tamsulosin/placebo group . Conclusions The association of tamsulosin/tadalafil reduces detrusor pressure at maximum flow without changing the maximum flow rate during micturition and significantly improves lower urinary tract symptoms compared with the isolated use of tamsulosin This prospect i ve study evaluated the safety of tadalafil 5 mg taken once a day in terms of hypotensive side effects and whether it improves lower urinary tract symptoms ( LUTS ) and restores sexual function in patients with erectile dysfunction who are receiving concomitant α-blocker ( AB ) therapy for benign prostatic hyperplasia ( BPH ) . A total of 158 LUTS/BPH patients receiving AB therapy for ≥3 months were given tadalafil 5 mg once a day . Before treatment with tadalafil ( V1 ) , and 4 weeks ( V2 ) and 12 weeks ( V3 ) after starting  tadalafil , blood pressure , heart rate , International Prostate Symptom Score ( IPSS ) , maximal urine flow rate ( Qmax ) , postvoiding residual urine volume , and International Index of Erectile Function ( IIEF-5 ) score were measured . Of the 158 LUTS/BPH patients , a total of 119 completed the trial . Blood pressure ( systolic and diastolic ) and heart rate did not change . IPSS and IIEF-5 scores improved significantly , but Qmax and postvoiding residual urine volume did not ; however , in the 39 men with a low baseline Qmax ( ≤10 mL/s ) , Qmax rose significantly from 7.97 ± 1.44 mL/s ( baseline ) to 8.91 ± 1.60 mL/s ( V3 ; P = .012 ) . The remaining patients ( baseline Qmax > 10 mL/s ) did not change . At V2 and V3 , adverse side effects were observed in 10 men ( 7.30 % ) and 6 men ( 5.04 % ) , respectively . Facial flushing was the most common adverse side effect ( 6 men at V2 and 4 men at V3 ) , followed by headache ( 2 men each at V2 and V3 ) and dizziness ( 2 men at V2 ) . Two patients dropped out of the study because of adverse side effects . In conclusion , tadalafil 5 mg once a day in combination with AB appeared to have few adverse effects on hypotensive events and can improve LUTS and restore sexual function Summary Aims / objectives : In the BESIDE study , combination therapy ( antimuscarinic [ solifenacin ] and β3‐adrenoceptor agonist [ mirabegron ] ) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder ( OAB ) patients ; however , a potential synergistic effect on the cardiovascular ( CV ) system requires investigation . Methods OAB patients remaining incontinent despite daily solifenacin 5 mg during 4‐week single‐blind run‐in , were r and omised 1:1:1 to double‐blind daily combination ( solifenacin 5 mg/mirabegron 25 mg , increasing to 50 mg after week 4 ) , solifenacin 5 or 10 mg for 12 weeks . CV safety assessment s included frequency of CV‐related treatment‐emergent adverse events ( TEAEs ) , change from baseline in vital signs ( systolic blood pressure [ SBP ] , diastolic blood pressure [ DBP ] , pulse rate ) and electrocardiogram ( ECG ) parameters . Results The frequency of hypertension , tachycardia and ECG QT prolongation , respectively , was low and comparable across combination ( 1.1 % , 0.3 % , 0.1 % ) , solifenacin 5 mg ( 0.7 % , 0.1 % , 0.1 % ) , and solifenacin 10 mg groups ( 0.8 % , 0 % , 0.1 % ) . Adjusted mean ( SE ) change from baseline to end of treatment ( EoT ) in SBP , DBP , and pulse rate with combination ( 0.07 mm Hg [ 0.38 ] , −0.35 mm Hg [ 0.26 ] , 0.47 bpm [ 0.28 ] ) , solifenacin 5 mg ( −0.93 mm Hg [ 0.38 ] , −0.45 mm Hg [ 0.26 ] , 0.43 bpm [ 0.28 ] ) and solifenacin 10 mg ( −1.28 mm Hg [ 0.38 ] , −0.48 mm Hg [ 0.26 ] , 0.27 bpm [ 0.28 ] ) was generally comparable , with the exception of a mean treatment difference of ~1 mm Hg in SBP between combination and solifenacin monotherapy ; SBP was unchanged with combination and decreased with solifenacin monotherapy . Mean changes from baseline to EoT in ECG parameters were generally similar across treatment groups , except for QT interval corrected using Fridericia 's formula , which was higher with solifenacin 10 mg ( 3.30 mseconds ) vs. combination ( 0.49 mseconds ) and solifenacin 5 mg ( 0.77 mseconds ) . Conclusion The comparable frequency of CV‐related TEAEs , changes in vital signs and ECG parameters indicates no synergistic effect on CV safety outcomes when mirabegron and solifenacin are combined PURPOSE We examined the effects of doxazosin , finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 ( Medical Outcomes Study Short-Form 36 ) and 2 disease specific instruments ( BII , benign prostatic hyperplasia Impact Index and I-PSS-QoL , International Prostate Symptom Score-QoL ) during 4 years . MATERIAL S AND METHODS The MTOPS ( Medical Therapy of Prostatic Symptoms ) study was a multicenter , r and omized , double-blind , placebo controlled clinical trial with a primary outcome of time to benign prostatic hyperplasia progression . Change in quality of life was a secondary outcome . A total of 2,872 men enrolled in the MTOPS study who had 3 baseline quality of life measures and at least 1 followup measure by any of the quality of life instruments were analyzed . RESULTS Compared with men assigned to placebo , men assigned to doxazosin and combination experienced a statistically significant improvement in the BII at year 4 . Men assigned to each of the drug groups also experienced a significant improvement in the I-PSS-QoL compared with those assigned to placebo . Considering longitudinal changes during 4 years , a significant improvement in BII and I-PSS-QoL scores was observed in men assigned to the drug groups compared with those assigned to placebo . However , there were no significant differences for the MOS-SF-36 subscales and summary scores when drug groups were compared with the placebo group . CONCLUSIONS The quality of life of men treated with doxazosin , finasteride , and the drugs combined generally improved when assessed with the BII and the I-PSS-QoL compared with those treated with placebo .  Quality of life did not show improvement when measured by the MOS-SF-36 BACKGROUND Combination therapy with dutasteride and tamsulosin provides significantly greater benefit than either monotherapy for various patient-reported outcomes in men with moderate-to-severe lower urinary tract symptoms ( LUTS ) due to benign prostatic hyperplasia ( BPH ) and prostatic enlargement . OBJECTIVE To investigate whether combination therapy is more effective than either monotherapy in reducing the relative risk for acute urinary retention ( AUR ) , BPH-related surgery , and BPH clinical progression over 4 yr in men at increased risk of progression . DESIGN , SETTING , AND PARTICIPANTS The Combination of Avodart and Tamsulosin ( CombAT ) study was a 4-yr , multicenter , r and omised , double-blind , parallel-group study in 4844 men > or = 50 yr of age with a clinical diagnosis of BPH , International Prostate Symptom Score > or = 12 , prostate volume > or = 30 cm(3 ) , prostate-specific antigen 1.5 - 10 ng/ml , and maximum urinary flow rate ( Q(max ) ) > 5 and < or = 15 ml/s with minimum voided volume > or = 125 ml . INTERVENTION Oral daily tamsulosin , 0.4 mg ; dutasteride , 0.5 mg ; or a combination of both . MEASUREMENTS The 4-yr primary end point was time to first AUR or BPH-related surgery . Secondary end points included BPH clinical progression , symptoms , Q(max ) , prostate volume , safety , and tolerability . RESULTS AND LIMITATIONS Combination therapy was significantly superior to tamsulosin monotherapy but not dutasteride monotherapy at reducing the relative risk of AUR or BPH-related surgery . Combination therapy was also significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression . Combination therapy provided significantly greater symptom benefit than either monotherapy at 4 yr . Safety and tolerability of combination therapy was consistent with previous experience with dutasteride and tamsulosin monotherapies , with the exception of an imbalance in the composite term of cardiac failure among the three study arms . The lack of placebo control is a study limitation . CONCLUSIONS The 4-yr CombAT data provide support for the long-term use of dutasteride and tamsulosin combination therapy in men with moderate-to-severe LUTS due to BPH and prostatic enlargement . CLINICAL TRIALS.GOV IDENTIFIER : NCT00090103 ( http://www . clinical trials.gov/ct2/show/NCT00090103 ) Objectives The aim of this study was to compare outcomes using two preference-based measures of health status ( EQ-5D-5L and OAB-5D ) in patients with overactive bladder ( OAB ) treated with solifenacin plus mirabegron or solifenacin monotherapy in the BESIDE trial . Methods Patients with OAB who remained incontinent after 4 weeks ’ treatment with solifenacin 5 mg were r and omized 1:1:1 to combination treatment ( solifenacin 5 mg plus mirabegron [ 25 mg for the first 4 weeks/50 mg for the last 8 weeks ] ) , solifenacin 5 mg , or solifenacin 10 mg . EQ-5D-5L and OAB-q were administered at baseline , weeks 4 , 8 , 12 , and end of treatment ( EoT ) . OAB-5D scores were derived from OAB-q results . Responder analysis was carried out using several definitions of minimally important difference . Results A total of 2054 patients received one or more doses of study treatment ( combination , n = 694 ; solifenacin 5 mg , n = 684 ; solifenacin 10 mg , n = 676 ) . EQ-5D-5L Index mean score changes ( from baseline to EoT ) were greater with combination ( 0.059 ) than with solifenacin 5 mg ( 0.040 ) and 10 mg ( 0.044 ) monotherapy , but the differences were not statistically significant . A significantly greater improvement was observed for combination on OAB-5D ( 0.107 vs 0.085 for 5 mg , and 0.087 for 10 mg ; p ≤ 0.01 ) . The dimensions most improved overall were anxiety/depression , pain/discomfort , and usual activities on EQ-5D-5L , and urge , urine loss , and coping on OAB-5D . The proportion of responders was significantly greater with combination compared with monotherapy using OAB-5D only . Conclusions Improvements were observed in all study arms on both the EQ-5D-5L and OAB-5D , although only the OAB-5D showed a statistically significant benefit for combination versus solifenacin monotherapy . Combining generic and condition-specific preference-based health status measures allowed for assessment of dimensions that were particularly relevant to this patient population , while permitting comparison with outcomes from other studies , treatments , and population s via EQ-5D Twenty-nine postmenopausal women with 
    Output:
    
agent
EVIDENCE SYNTHESIS The most studied combination therapy for the treatment of male LUTS is the α1-adrenoceptor antagonist/5α-reductase inhibitor combination .
This combination seems to be more efficacious in terms of several outcome variables , in particular in men who have moderate-to-severe LUTS and are at risk of disease progression .
Also in terms of nocturia improvements , this combination is significantly more effective than the monotherapy .
The other often studied combination treatment , in both male and female patients with LUTS , was the combination of antimuscarinics ( in particular solifenacin ) and mirabegron .
This combination seems to be more effective in comparison with the monotherapies with respect to urinary incontinence and urgency urinary incontinence episodes and several other objective and subjective parameters , without relevant increase of adverse events .
The combination of hormone therapy and antimuscarinics in women with LUTS does not seem to be useful .
For the treatment of LUTS in men and women , combination therapy appears to be a promising option to optimize the efficacy of the available drugs for those who do not experience sufficient benefit with monotherapy .
This add-on scenario offers the possibility to have a more tailored approach to the management of LUTS , always seeking the optimal balance between efficacy and tolerability for a given patient .
PATIENT SUMMARY Some combination of drugs may offer advantages over monotherapies for the treatment of voiding and storage complaints in men and women
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Objectives To evaluate the effect of association of tamsulosin/tadalafil taken daily compared with tamsulosin/placebo in the lower urinary tract with urodynamic study ( UDS ) . Methods All patients underwent baseline UDS before r and omization to tamsulosin 0.4 mg/tadalafil 5 mg ( Group 1 ; n = 20 ) or tamsulosin 0.4 mg/placebo ( Group 2 ; n = 20 ) once daily for 30 days . End-of- study UDS were performed on completion of the treatment period . The primary end point was to demonstrate changes in urodynamic variables in the voiding phase , detrusor pressure at maximum flow ( PdetQmax ) , and maximum flow rate ( Qmax ) , from baseline to week four . Results The primary outcome measure of this clinical trial , PdetQmax , showed a significant reduction in tamsulosin/tadalafil group ( 13 ± 17.0 ) compared to tamsulosin/placebo ( −1.2 ± 14.35 ) group ( P = 0.03 ) . Qmax increased in both groups , tamsulosin/tadalafil ( 1.0 ± 2.4 ) and tamsulosin/placebo ( 1.4 ± 2.4 ) , but the difference was not significant between treatment groups ( P = 0.65 ) . Total IPSS , storage , and voiding sub-score improved significantly in tamsulosin/tadalafil compared with tamsulosin/placebo group . Conclusions The association of tamsulosin/tadalafil reduces detrusor pressure at maximum flow without changing the maximum flow rate during micturition and significantly improves lower urinary tract symptoms compared with the isolated use of tamsulosin This prospect i ve study evaluated the safety of tadalafil 5 mg taken once a day in terms of hypotensive side effects and whether it improves lower urinary tract symptoms ( LUTS ) and restores sexual function in patients with erectile dysfunction who are receiving concomitant α-blocker ( AB ) therapy for benign prostatic hyperplasia ( BPH ) . A total of 158 LUTS/BPH patients receiving AB therapy for ≥3 months were given tadalafil 5 mg once a day . Before treatment with tadalafil ( V1 ) , and 4 weeks ( V2 ) and 12 weeks ( V3 ) after starting  tadalafil , blood pressure , heart rate , International Prostate Symptom Score ( IPSS ) , maximal urine flow rate ( Qmax ) , postvoiding residual urine volume , and International Index of Erectile Function ( IIEF-5 ) score were measured . Of the 158 LUTS/BPH patients , a total of 119 completed the trial . Blood pressure ( systolic and diastolic ) and heart rate did not change . IPSS and IIEF-5 scores improved significantly , but Qmax and postvoiding residual urine volume did not ; however , in the 39 men with a low baseline Qmax ( ≤10 mL/s ) , Qmax rose significantly from 7.97 ± 1.44 mL/s ( baseline ) to 8.91 ± 1.60 mL/s ( V3 ; P = .012 ) . The remaining patients ( baseline Qmax > 10 mL/s ) did not change . At V2 and V3 , adverse side effects were observed in 10 men ( 7.30 % ) and 6 men ( 5.04 % ) , respectively . Facial flushing was the most common adverse side effect ( 6 men at V2 and 4 men at V3 ) , followed by headache ( 2 men each at V2 and V3 ) and dizziness ( 2 men at V2 ) . Two patients dropped out of the study because of adverse side effects . In conclusion , tadalafil 5 mg once a day in combination with AB appeared to have few adverse effects on hypotensive events and can improve LUTS and restore sexual function Summary Aims / objectives : In the BESIDE study , combination therapy ( antimuscarinic [ solifenacin ] and β3‐adrenoceptor agonist [ mirabegron ] ) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder ( OAB ) patients ; however , a potential synergistic effect on the cardiovascular ( CV ) system requires investigation . Methods OAB patients remaining incontinent despite daily solifenacin 5 mg during 4‐week single‐blind run‐in , were r and omised 1:1:1 to double‐blind daily combination ( solifenacin 5 mg/mirabegron 25 mg , increasing to 50 mg after week 4 ) , solifenacin 5 or 10 mg for 12 weeks . CV safety assessment s included frequency of CV‐related treatment‐emergent adverse events ( TEAEs ) , change from baseline in vital signs ( systolic blood pressure [ SBP ] , diastolic blood pressure [ DBP ] , pulse rate ) and electrocardiogram ( ECG ) parameters . Results The frequency of hypertension , tachycardia and ECG QT prolongation , respectively , was low and comparable across combination ( 1.1 % , 0.3 % , 0.1 % ) , solifenacin 5 mg ( 0.7 % , 0.1 % , 0.1 % ) , and solifenacin 10 mg groups ( 0.8 % , 0 % , 0.1 % ) . Adjusted mean ( SE ) change from baseline to end of treatment ( EoT ) in SBP , DBP , and pulse rate with combination ( 0.07 mm Hg [ 0.38 ] , −0.35 mm Hg [ 0.26 ] , 0.47 bpm [ 0.28 ] ) , solifenacin 5 mg ( −0.93 mm Hg [ 0.38 ] , −0.45 mm Hg [ 0.26 ] , 0.43 bpm [ 0.28 ] ) and solifenacin 10 mg ( −1.28 mm Hg [ 0.38 ] , −0.48 mm Hg [ 0.26 ] , 0.27 bpm [ 0.28 ] ) was generally comparable , with the exception of a mean treatment difference of ~1 mm Hg in SBP between combination and solifenacin monotherapy ; SBP was unchanged with combination and decreased with solifenacin monotherapy . Mean changes from baseline to EoT in ECG parameters were generally similar across treatment groups , except for QT interval corrected using Fridericia 's formula , which was higher with solifenacin 10 mg ( 3.30 mseconds ) vs. combination ( 0.49 mseconds ) and solifenacin 5 mg ( 0.77 mseconds ) . Conclusion The comparable frequency of CV‐related TEAEs , changes in vital signs and ECG parameters indicates no synergistic effect on CV safety outcomes when mirabegron and solifenacin are combined PURPOSE We examined the effects of doxazosin , finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 ( Medical Outcomes Study Short-Form 36 ) and 2 disease specific instruments ( BII , benign prostatic hyperplasia Impact Index and I-PSS-QoL , International Prostate Symptom Score-QoL ) during 4 years . MATERIAL S AND METHODS The MTOPS ( Medical Therapy of Prostatic Symptoms ) study was a multicenter , r and omized , double-blind , placebo controlled clinical trial with a primary outcome of time to benign prostatic hyperplasia progression . Change in quality of life was a secondary outcome . A total of 2,872 men enrolled in the MTOPS study who had 3 baseline quality of life measures and at least 1 followup measure by any of the quality of life instruments were analyzed . RESULTS Compared with men assigned to placebo , men assigned to doxazosin and combination experienced a statistically significant improvement in the BII at year 4 . Men assigned to each of the drug groups also experienced a significant improvement in the I-PSS-QoL compared with those assigned to placebo . Considering longitudinal changes during 4 years , a significant improvement in BII and I-PSS-QoL scores was observed in men assigned to the drug groups compared with those assigned to placebo . However , there were no significant differences for the MOS-SF-36 subscales and summary scores when drug groups were compared with the placebo group . CONCLUSIONS The quality of life of men treated with doxazosin , finasteride , and the drugs combined generally improved when assessed with the BII and the I-PSS-QoL compared with those treated with placebo .  Quality of life did not show improvement when measured by the MOS-SF-36 BACKGROUND Combination therapy with dutasteride and tamsulosin provides significantly greater benefit than either monotherapy for various patient-reported outcomes in men with moderate-to-severe lower urinary tract symptoms ( LUTS ) due to benign prostatic hyperplasia ( BPH ) and prostatic enlargement . OBJECTIVE To investigate whether combination therapy is more effective than either monotherapy in reducing the relative risk for acute urinary retention ( AUR ) , BPH-related surgery , and BPH clinical progression over 4 yr in men at increased risk of progression . DESIGN , SETTING , AND PARTICIPANTS The Combination of Avodart and Tamsulosin ( CombAT ) study was a 4-yr , multicenter , r and omised , double-blind , parallel-group study in 4844 men > or = 50 yr of age with a clinical diagnosis of BPH , International Prostate Symptom Score > or = 12 , prostate volume > or = 30 cm(3 ) , prostate-specific antigen 1.5 - 10 ng/ml , and maximum urinary flow rate ( Q(max ) ) > 5 and < or = 15 ml/s with minimum voided volume > or = 125 ml . INTERVENTION Oral daily tamsulosin , 0.4 mg ; dutasteride , 0.5 mg ; or a combination of both . MEASUREMENTS The 4-yr primary end point was time to first AUR or BPH-related surgery . Secondary end points included BPH clinical progression , symptoms , Q(max ) , prostate volume , safety , and tolerability . RESULTS AND LIMITATIONS Combination therapy was significantly superior to tamsulosin monotherapy but not dutasteride monotherapy at reducing the relative risk of AUR or BPH-related surgery . Combination therapy was also significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression . Combination therapy provided significantly greater symptom benefit than either monotherapy at 4 yr . Safety and tolerability of combination therapy was consistent with previous experience with dutasteride and tamsulosin monotherapies , with the exception of an imbalance in the composite term of cardiac failure among the three study arms . The lack of placebo control is a study limitation . CONCLUSIONS The 4-yr CombAT data provide support for the long-term use of dutasteride and tamsulosin combination therapy in men with moderate-to-severe LUTS due to BPH and prostatic enlargement . CLINICAL TRIALS.GOV IDENTIFIER : NCT00090103 ( http://www . clinical trials.gov/ct2/show/NCT00090103 ) Objectives The aim of this study was to compare outcomes using two preference-based measures of health status ( EQ-5D-5L and OAB-5D ) in patients with overactive bladder ( OAB ) treated with solifenacin plus mirabegron or solifenacin monotherapy in the BESIDE trial . Methods Patients with OAB who remained incontinent after 4 weeks ’ treatment with solifenacin 5 mg were r and omized 1:1:1 to combination treatment ( solifenacin 5 mg plus mirabegron [ 25 mg for the first 4 weeks/50 mg for the last 8 weeks ] ) , solifenacin 5 mg , or solifenacin 10 mg . EQ-5D-5L and OAB-q were administered at baseline , weeks 4 , 8 , 12 , and end of treatment ( EoT ) . OAB-5D scores were derived from OAB-q results . Responder analysis was carried out using several definitions of minimally important difference . Results A total of 2054 patients received one or more doses of study treatment ( combination , n = 694 ; solifenacin 5 mg , n = 684 ; solifenacin 10 mg , n = 676 ) . EQ-5D-5L Index mean score changes ( from baseline to EoT ) were greater with combination ( 0.059 ) than with solifenacin 5 mg ( 0.040 ) and 10 mg ( 0.044 ) monotherapy , but the differences were not statistically significant . A significantly greater improvement was observed for combination on OAB-5D ( 0.107 vs 0.085 for 5 mg , and 0.087 for 10 mg ; p ≤ 0.01 ) . The dimensions most improved overall were anxiety/depression , pain/discomfort , and usual activities on EQ-5D-5L , and urge , urine loss , and coping on OAB-5D . The proportion of responders was significantly greater with combination compared with monotherapy using OAB-5D only . Conclusions Improvements were observed in all study arms on both the EQ-5D-5L and OAB-5D , although only the OAB-5D showed a statistically significant benefit for combination versus solifenacin monotherapy . Combining generic and condition-specific preference-based health status measures allowed for assessment of dimensions that were particularly relevant to this patient population , while permitting comparison with outcomes from other studies , treatments , and population s via EQ-5D Twenty-nine postmenopausal women with 
    Output:
    